🔗 Share this article New Antimicrobials Celebrated as a 'Pivotal Moment' in Treating Antibiotic-Resistant Gonorrhoea The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to health experts. A Worldwide Challenge Gonorrhoea infections are increasing globally, with data suggesting in excess of 82 million infections annually. Notably increased rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014. “The approval of novel therapies for gonorrhoea is an important and timely development in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.” Public health authorities are increasingly worried about the surge in drug-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance revealed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024. Two New Therapies Gain Authorization Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts hope that focused deployment of this new drug will help slow the spread of drug resistance. Gepotidacin, created by the pharmaceutical company GSK, gained clearance in close succession. This treatment, which is also used to treat UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria. A Novel Development Model Zoliflodacin stemmed from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition. “This authorization marks a huge turning point in the management of multidrug-resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.” Research Study Results and Global Access According to findings detailed in a major medical journal, the new drug successfully treated more than 90% of uncomplicated infections. This places it at an equal footing with the typical regimen, which uses two antibiotics. The research involved over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US. Under the terms of its unique model, the non-profit has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries. Medical professionals directly involved have expressed positive views. Access to a easy-to-administer therapy of this kind is described as a "game-changer" for managing the epidemic. This is deemed essential to reduce the burden of the infection for people and to halt the transmission of extremely resistant gonorrhoea around the world.